Bobby Sheng is the Chairman of Bora Biologics and the CEO of Bora Group, where he also serves as Chairman of Bora Pharmaceuticals Inc. With over 25 years of experience in the pharmaceutical industry, Bobby has successfully guided the organic and inorganic growth of Bora Biologics through successful partnerships. A California native and seasoned leader, Bobby is a serial entrepreneur with a track record of successful ventures, including introducing Kiehl’s to the Taiwan market and co-founding the music label Machi. He has been involved in numerous successful startups in the IT and entertainment sectors. Bobby’s expertise spans international business, management, mergers and acquisitions, finance, and marketing. He holds a Bachelor’s Degree from the University of California, Berkeley.

Stephen Lam is the Chief Executive Officer (CEO) at Bora Biologics. He is responsible for driving the company’s strategic initiatives as well as overseeing day-to-day operations, including Bora Biologics’ global CDMO operations, as well as the commercialization of the biosimilar pipeline. With over 35 years in the biopharmaceutical industry at leading companies including Lonza, Amgen, and Patheon, Stephen has built a strong track record of delivering results. More recently, he served as Vice President and General Manager, Head of Biologics at Thermo Fisher Scientific.

Angela Luan is a dynamic leader, currently serving as Chief Financial Officer at Bora Biologics. Angela holds degrees from National Chengchi University and National Taiwan University. She has cultivated her expertise through various roles in investor relations and corporate communications. Her passion for strategic partnerships has contributed to the success of Bora Biologics.

Marc Goemans serves as the Chief Commercialization Officer at Bora Biologics, where he leverages his 25 years in the biopharmaceutical sector to drive the successful market introduction of new products. In this role, Marc is responsible for developing and executing commercialization strategies that ensure Bora Biologics meets the evolving needs of its clients and the broader market. Prior to joining Bora Biologics, Marc held senior leadership positions at DSM Biologics, Patheon, Consort Medical and Catalent. His expertise spans both drug substance as well as drug product, enabling him to navigate the complexities of bringing innovative solutions to market effectively. Marc is committed to fostering a collaborative environment that emphasizes cross-functional teamwork and strategic partnerships. He believes that strong relationships with clients and stakeholders are crucial for achieving commercial success. With MSc degrees in Engineering and Business Administration, Marc combines his technical knowledge with a keen understanding of market dynamics, positioning Bora Biologics for continued growth and leadership in the biopharmaceutical industry.

John Mosack is the General Manager & Vice President Operations for Bora Biologics San Diego site, bringing over 30 years of operations management experience in the biopharmaceutical industry for both drug substance and drug product facilities. Prior to joining Bora Biologics, he held pivotal roles at Catalent Biologics, Lonza, Inc., Bristol-Myers Squibb, and PAREXEL. His extensive expertise spans various biologic modalities (antibodies, cell, and gene therapy) as well as technology platforms (mammalian, microbial fermentation). John has led organizations successfully through state-of-the-art facility start- ups, drug development lifecycle transitions (clinical to commercial), multiple product licensures, operational efficiencies and technology transitions. John believes a key to success is cultivating a focused, collaborative, and diverse team aligned with the strategic plan of an organization.

Dr. Spitznagel, Senior Vice President, Technical Operations, joined the Rockville operations in 2013. He has overall responsibility for biopharmaceutical development and manufacturing of the Fc-optimized monoclonal antibodies, DART® molecules, and Antibody Drug Conjugates, as well as quality, supply chain, CMC project management, facilities and engineering. Prior to joining us, he was at Human Genome Sciences, most recently serving as Vice President of BioPharmaceutical Development, where he was responsible for oversight of Analytical Development, Formulation and Drug Delivery, Purification Sciences, and Fermentation and Cell Culture Sciences. Prior to joining HGS, Dr. Spitznagel was a Senior Scientist at Nabi from 1996-1998, and a Staff Engineer at Genetics Institute from 1992-1996. Dr. Spitznagel earned his BS in Chemical Engineering at M.I.T, and his Ph.D. in Chemical Engineering at the University of California, Berkeley.

Jennifer Kuan is the Vice President of Operations at Bora Biologics Taiwan, bringing over a decade of leadership experience in the biologics sector. She has a strong technical foundation in process development, manufacturing, and technical operations, with a proven track record of delivering site performance through both strategic insight and operational execution.

Prior to joining Bora Biologics, Jennifer held key leadership roles at PharmaEssentia and JHL Biotech, where she led the design, construction, and startup of state-of-the-art biologics facilities built to global regulatory standards—including JHL’s commercial manufacturing site in China. Her expertise centers on early-phase clinical manufacturing, where development speed, technical agility, and uncompromising quality are critical.

Jennifer is committed to building high-performing, time-disciplined teams and fostering a culture of accountability, innovation, and continuous improvement. With strong cross-functional leadership and a client-focused mindset, she ensures the Taiwan site consistently meets the evolving needs of biopharma partners worldwide.

Miguel Carrion is Vice President of Process Development & MSAT at Bora Biologics. He brings over 30 years of experience in Research & Development, Process Development and Manufacturing. Before joining Bora Biologics, Miguel held various leadership positions in the biopharma services industry, including General Manager and Director of Operations at Thermo Fisher Scientific, Site Head and Director of MSAT at Catalent, Director of Manufacturing at ATCC, and Director of Operations at Precision for Medicine. He has made significant contributions to the fields of cell & gene therapy and biologics, employing innovative analytical methods, upstream and downstream technologies for the production and purification of biopharmaceuticals. His work also resulted in the discovery of VEGFR2/KDR, a pivotal target in cancer therapy. Miguel’s expertise spans process optimization, scale-up, and technology transfer, reflected in his impressive portfolio of 9 US patents and multiple publications. Throughout his career, Miguel has played a key role in multiple IND submissions and commercial product launches, assisting customers in bringing advanced therapies to market.